Skip Navigation LinksHome > June 2014 - Volume 21 - Issue 6 > Phase 3 randomized controlled study of gastroretentive gabap...
Menopause:
doi: 10.1097/GME.0b013e3182a7c073
Original Articles

Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause

Pinkerton, JoAnn V. MD1; Kagan, Risa MD2; Portman, David MD3; Sathyanarayana, Rekha BS4; Sweeney, Michael MD4

Supplemental Author Material
Editorial
Collapse Box

Abstract

Objective

The goal of this study was to evaluate the efficacy and safety of gastroretentive gabapentin (G-GR) for the treatment of moderate-to-severe menopausal hot flashes.

Methods

The primary endpoints of this randomized, placebo-controlled study of G-GR (600 mg am/1,200 mg pm) were the mean daily frequency and severity of hot flashes at weeks 4 and 12. Secondary endpoints included Patients’ Global Impression of Change, Clinicians’ Global Impression of Change, and daily sleep interference at week 24.

Results

Six hundred women with 7 or more moderate-to-severe hot flashes/day enrolled; 66.2% completed 24 weeks of treatment. At weeks 4 and 12, G-GR–treated women experienced significantly greater reductions in mean hot flash frequency and severity than placebo-treated women (frequency: week 4, −1.7, P < 0.0001; week 12, −1.14, P = 0.0007; severity: week 4, −0.21, P < 0.0001; week 12, −0.19, P = 0.012). Similar reductions were maintained up to week 24. On the Patient Global Impression of Change, more women receiving G-GR than placebo were “much” or ”very much” improved (week 12: 58% vs 44%, P = 0.0008; week 24: 76% vs 55%, P < 0.0001). G-GR significantly reduced sleep interference compared with placebo at week 12 (P = 0.0056) and week 24 (P = 0.0084). Approximately 5% more women taking G-GR withdrew because of adverse events (G-GR/placebo, 16.7%/11.5%). The most common adverse events were dizziness (12.7%/3.4%), headache (9.3%/8.1%), and somnolence (6.0%/2.7%); incidences dropped to sustained low levels after a few weeks.

Conclusions

G-GR is a modestly effective nonhormone therapy option for the treatment of moderate-to-severe hot flashes due to menopause and is well tolerated with titration.

© 2013 by The North American Menopause Society

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.